Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population

被引:121
作者
Hiratsuka, M
Takekuma, Y
Endo, N
Narahara, K
Hamdy, SI
Kishikawa, Y
Matsuura, M
Agatsuma, Y
Inoue, T
Mizugaki, M
机构
[1] Tohoku Univ Hosp, Dept Pharmaceut Sci, Aoba Ku, Sendai, Miyagi 9808574, Japan
[2] Tohoku Pharmaceut Univ, Dept Clin Pharmaceut, Sendai, Miyagi 9818558, Japan
关键词
pharmacogenetics; CYP2B6; CYP3A5;
D O I
10.1007/s00228-002-0499-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: The goal of this study was to determine the frequencies of allelic variants of CYP2B6 and CYP3A5 in the Japanese population. Methods: Genotyping of CYP2B6 (*2, *3, *4, *5, *6, and *7)and CYP3A5 (*2, *3, *4, *5, and *6) was carried out in 265 unrelated Japanese subjects by polymerase chain reaction (PCR), restriction fragment length polymorphism and allele-specific, real-time PCR assays. Results: Allele frequencies for CYP2B6*2, *3, *4, *5, *6, and *7 in 256 Japanese subjects were 0.047, 0, 0.093, 0.011, 0.164, and 0, respectively. Ethnic variation in allele frequencies relative to that in Caucasian subjects was observed for CYP2B6*4 (0.093 vs 0.040), *5 (0.011 vs 0.109), *6 (0.164 vs 0.256), and *7 (0 vs 0.030). Allele frequencies for CYP3A5*2, *3, *4, *5, and *6 in 265 Japanese subjects were 0, 0.740, 0, 0.004, and 0, respectively. The frequency of the CYP3A5*1 allele is 2.8 times higher in Japanese than in Caucasians. Conclusions: Our results contribute to a better understanding of the molecular basis of ethnic differences in drug response, which may help to improve individualization of drug therapy and offer a preliminary basis for more rational use of drugs that are substrates for CYP2B6 and CYP3A5 in the Japanese population.
引用
收藏
页码:417 / 421
页数:5
相关论文
共 16 条
  • [1] A single nucleotide polymorphism of CYP2B6 found in Japanese enhances catalytic activity by autoactivation
    Ariyoshi, N
    Miyazaki, M
    Toide, K
    Sawamura, Y
    Kamataki, T
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 281 (05) : 1256 - 1260
  • [2] CHANG TKH, 1993, CANCER RES, V53, P5629
  • [3] Chou FC, 2001, DRUG METAB DISPOS, V29, P1205
  • [4] Faucette SR, 2000, DRUG METAB DISPOS, V28, P1222
  • [5] Genomic organization of the human CYP3A locus:: identification of a new, inducible CYP3A gene
    Gellner, K
    Eiselt, R
    Hustert, E
    Arnold, H
    Koch, I
    Haberl, M
    Deglmann, CJ
    Burk, O
    Buntefuss, D
    Escher, S
    Bishop, C
    Koebe, HG
    Brinkmann, U
    Klenk, HP
    Kleine, K
    Meyer, UA
    Wojnowski, L
    [J]. PHARMACOGENETICS, 2001, 11 (02): : 111 - 121
  • [6] Granvil CP, 1999, DRUG METAB DISPOS, V27, P533
  • [7] GENE STRUCTURE OF CYP3A4, AN ADULT-SPECIFIC FORM OF CYTOCHROME-P450 IN HUMAN LIVERS, AND ITS TRANSCRIPTIONAL CONTROL
    HASHIMOTO, H
    TOIDE, K
    KITAMURA, R
    FUJITA, M
    TAGAWA, S
    ITOH, S
    KAMATAKI, T
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1993, 218 (02): : 585 - 595
  • [8] Hesse LM, 2000, DRUG METAB DISPOS, V28, P1176
  • [9] Hiratsuka M, 2000, BIOL PHARM BULL, V23, P1131
  • [10] Detection of a CYP3A5 allelic variant: A candidate for the polymorphic expression of the protein?
    Jounaidi, Y
    Hyrailles, V
    Gervot, L
    Maurel, P
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 221 (02) : 466 - 470